Oncotelic Reports Clinical Validation of Drug Induce Xenogenization (DIX) For Treatment of Glioblastoma and Pancreatic Cancer (PC)
March 04, 2019 09:00 ET | Oncotelic Inc
Phase 2 Clinical Data Presented at ASCO-SITC Clinical Immuno-Oncology SymposiumXenogenization through chemotherapy-induced genetic mutations (alkylating agents such as temozolomide) or drug-induced...
Oncotelic Reports that It's Proprietary In-Situ Cancer Vaccine Improved Survival over Standard Chemotherapy in Patients with Recurrent Metastatic Pancreas Cancer and Recurrent High Grade Glioma
February 13, 2019 09:15 ET | Oncotelic Inc
Phase 2 Clinical Data Presented at 11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research:Biology to Precision MedicineOT-101 exhibited promising single agent clinical activity as second...
Oncotelic Inc. Announces Appointment of Fatih Uckun MD PhD to Chief Medical Officer
January 22, 2019 09:15 ET | Oncotelic Inc
AGOURA HILLS, Calif, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic), a privately held cancer immunotherapy company dedicated to the discovery and development of in situ cancer...